Premium
Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin–tazobactam
Author(s) -
Chris Settle,
Mark H. Wilcox,
Warren N. Fawley,
O J Corrado,
Peter M. Hawkey
Publication year - 1998
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1998.00428.x
Subject(s) - medicine , piperacillin/tazobactam , cefotaxime , clostridium difficile , piperacillin , prospective cohort study , tazobactam , clostridium infections , diarrhea , antibiotics , intensive care medicine , gastroenterology , microbiology and biotechnology , bacteria , genetics , pseudomonas aeruginosa , biology
Background Rates of Clostridium difficile diarrhoea have recently been rising, with the elderly being at highest risk. Aim To compare the incidence of C. difficile colonization and diarrhoea in elderly patients treated for presumed infection with either empirical cefotaxime (CTX) or piperacillin–tazobactam (PT). Methods A prospective, ward‐based, crossover study was carried out on two well‐matched care of the elderly wards at a UK tertiary care hospital, in patients requiring empirical broad‐spectrum antibiotic treatment. Results There was a highly significant increased incidence of C. difficile colonization (26/34 vs. 3/14, P = 0.001) and diarrhoea (18/34 vs. 1/14, P = 0.006) in patients who received CTX as opposed to PT. DNA fingerprinting suggested that most infections arose from strains acquired from the hospital environment. Conclusions Elderly patients are significantly less likely to develop C. difficile diarrhoea after treatment with PT than after CTX. The source of C. difficile appears to be predominantly from the ward environment.